Companies attract venture funding for redesigned psychedelic drugs
![](https://www.lophora.com/wp-content/uploads/2024/06/Lophora-Scientific-American-Logo-1024x513.jpg)
CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 in the landscape of next generation psychedelics. https://www.scientificamerican.com/article/should-next-generation-psychedelics-skip-the-trip
Lophora submits CTA Application for LPH-5 directed towards a Phase I study
![](https://www.lophora.com/wp-content/uploads/2024/06/Lophora-MedWatch-Logo-1024x512.jpg)
Lophora interviewed by Medwatch (in Danish) https://medwatch.dk/Medicinal___Biotek/article17157459.ece
Next-generation psychedelics: should new agents skip the trip?
![](https://www.lophora.com/wp-content/uploads/2024/06/Lophora-Nature-Biotechnology-Logo-1024x512.jpg)
CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 inthe landscape of next generation psychedelics. https://www.nature.com/articles/s41587-024-02285-1
Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.
![Lophora Liber herbarium](https://www.lophora.com/wp-content/uploads/2024/05/Lophora-Liber-herbarium-1024x512.jpg)
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders, announced today that it has submitted a Clinical Trial Application (CTA) for its lead drug program LPH-5. The CTA is directed towards a Phase I first-in-human study to assess the safety, tolerability, pharmacokinetics and potential […]
Structure-Activity Relationships of Lophora’s selective serotonin 5-HT2A receptor agonists published in the Journal of Medicinal Chemistry
![Lophora Forest morning](https://www.lophora.com/wp-content/uploads/2024/05/Lophora-Forest-morning-1024x512.jpg)
The Lophora team has published a paper detailing the discovery and structure of the lead clinical candidate LPH-5 in the Journal of Medicinal Chemistry. The Lophora team is pleased to announce the publication detailing the discovery and structure of our lead clinical candidate LPH-5 in this month’s Journal of Medicinal Chemistry. LPH-5 is a […]
Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I
![Lophora White flowers](https://www.lophora.com/wp-content/uploads/2023/08/Lophora-White-flowers-1024x512.jpg)
Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark, Lophora has received additional support of ~US$1M from a syndicate of family offices and experienced biotech investors. The new investment allows Lophora to strengthen its global composition of matter patent portfolio and produce GMP-grade drug product of its first-in-class lead candidate LPH-5, which is ready to enter Phase I studies.
Lophora completes preclinical development of LPH-5 for treatment-resistant depression
![Lophora Oak Bark](https://www.lophora.com/wp-content/uploads/2022/11/Lophora-Oak-Bark-1024x512.jpg)
Lophora has completed the pre-clinical development of its first-in-class lead candidate LPH-5 for Treatment Resistant Depression. No toxicology or histopathology findings.
Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression
![Lophora Alhambra wall](https://www.lophora.com/wp-content/uploads/2021/03/Lophora-Alhambra-wall-1024x512.jpg)
Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation Initiative), Lophora has received additional support of US$1.6M from The Danish Growth Fund (Vækstfonden) and the Danish Innovation Fund (Innovationsfonden), allowing Lop hora to complete pre-clinical development of its first-in-class lead candidate LPH-5, which is expected to enter Phase I studies in early 2022.
Lophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression
![](https://www.lophora.com/wp-content/uploads/2020/04/Lophora-Spiral-stairs-1024x512.jpg)
Lophora has been granted a $1.5M convertible loan by the Novo Nordisk Foundation to advance their first-in-class lead candidate LPH-5.
In early 2020, Lophora was successfully accepted into the Creation House program at BioInnovation Institute and granted a $1.5M convertible loan by the Novo Nordisk Foundation.
Lophora will now advance their lead candidate LPH-5 through pre-clinical development in order to de-risk the compound prior to the initiation of first-in-human studies towards the end of 2021. Amongst other things, this involves the large-scale production of LPH-5, followed by a detailed characterization of the molecule’s safety profile, which is a key regulatory requirement prior to initiating clinical studies.